Literature DB >> 16545501

[Autoimmune hepatitis in a HIV-HCV co-infected patient: diagnostic ant therapeutic difficulties].

C Cazanave1, S Rakotondravelo, P Morlat, P Blanco, F Bonnet, J Beylot.   

Abstract

INTRODUCTION: Autoimmune hepatitis (AIH) is a chronic inflammatory hepatic disorder, characterized by hypergammaglobulinemia and autoantibodies. In some cases, AIH can be associated with another liver disease; such as the hepatitis C-AIH overlap syndrome, which diagnosis and treatment may be delicate. EXEGESE: We report a type 1 AIH case in a HIV-HCV co-infected woman. AIH remission and HCV eradication were obtained with prednisone and interferon plus ribavirine. AIH relapse appeared with corticosteroid withdrawal and a new remission was obtained with immunosuppressive treatment associating prednisone and azathioprine, without opportunistic infection.
CONCLUSION: This case illustrates diagnostic and therapeutic difficulties of hepatitis C-AIH overlap syndromes in an HIV-infected patient. To our knowledge, it is the first AIH case report in a HIV-HCV co-infected patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545501     DOI: 10.1016/j.revmed.2006.01.016

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  3 in total

1.  Human immunodeficiency virus infection and autoimmune hepatitis during highly active anti-retroviral treatment: a case report and review of the literature.

Authors:  Hanady Daas; Riad Khatib; Haitham Nasser; Farah Kamran; Martha Higgins; Louis Saravolatz
Journal:  J Med Case Rep       Date:  2011-06-25

2.  Concurrent autoimmune hepatitis and grave's disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy.

Authors:  Guru V Trikudanathan; Imad Ahmad; Jonathan L Israel
Journal:  Saudi J Gastroenterol       Date:  2011 Sep-Oct       Impact factor: 2.485

Review 3.  Autoimmune hepatitis in human immunodeficiency virus-infected patients: A case series and review of the literature.

Authors:  Roongruedee Chaiteerakij; Anapat Sanpawat; Anchalee Avihingsanon; Sombat Treeprasertsuk
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.